Research Article

Malaria Parasite Density as a Predictor of Hematological Parameter Changes among HIV Infected Adults Attending Two Antiretroviral Treatment Clinics in Kano, Northwest Nigeria

Feyisayo E. Jegede,1,2 Tinuade I. Oyeyi,2 Surajudeen A. Abdulrahman,3 and Henry A. Mbah4

1Family Health International-360, Plot 1073-A1 GODAB Plaza, Area 3 Garki-Abuja, Abuja, Nigeria
2Biological Science Department, Bayero University Kano, Kano, Nigeria
3Health Education England, East of England, 2-4 Victoria House, Capital Park, Fulbourn, Cambridge CB21 5XB, UK
4LabTrail, Global LLC, Smyrna, DE, USA

Correspondence should be addressed to Feyisayo E. Jegede; feyisayojegede@gmail.com

Received 5 September 2019; Accepted 8 February 2020; Published 27 April 2020

Academic Editor: Sukla Biswas

Copyright © 2020 Feyisayo E. Jegede et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Despite public health significance of dual infections of human immunodeficiency virus (HIV) and malaria in developing countries like Nigeria, information on the association between malaria parasite density count (MPDC) and hematological parameter changes among HIV-infected individuals is rarely available. Objectives. To evaluate burden of HIV and malaria dual infections and assess the predictive association of MPDC with hematological parameter changes among HIV infected adults attending two antiretroviral treatment clinics in Kano, Nigeria. Methodology. This was a cross-sectional study consisting of 1521 consented participants randomly selected between June 2015 and May 2016. Participants’ basic characteristics and clinical details were collected using a pretested and validated standardized questionnaire. Collected venous blood was analyzed for malaria by rapid testing and microscopy including malaria parasite density; hematological parameters were estimated using a Sysmex XP-300 autoanalyzer. Data was reviewed, cleaned, and analyzed using SPSS software version 23.0. Mean hematological parameters and HIV/malaria status were compared using the independent t-test; hematological parameters and MPDC relationship was tested by simple linear regression analysis. Statistically significant difference at probability of <0.05 was considered for all variables.

Results. The majority (70.6%) of the participants were females. Mean (SD) age was 37.30 ± 10.41 years and ranged from 18 to 78 years. 25.4% of participants had dual infection, 99% due to Plasmodium falciparum species. Mean MPDC was 265 ± 31.8 (SD) cells/μl and ranged from 20 to 2500 cells/μl. Dual infection was highest (37.5%) among respondents in the age group ≥60 years. Prevalence was similar among other age groups (p = 0.165) and gender (p = 0.942). Of the 16 hematological parameters evaluated, 11 showed significant difference between HIV mono-infected and dual infected participants. Of the 11 parameters, only 7 (Hb, MCHC, red cells count, neutrophil and lymphocyte percentage, absolute lymphocyte count, and red cell distribution width) were significantly predictive of changes with respect to MPDC. Conclusions. MPDC was significantly predictive of changes in 7 hematological parameters among dual infected participants in these settings. In routine malaria diagnosis, MPDC determination with respect to changes in some hematological parameters should be considered in ART programs for improved patient management.

1. Introduction

Human immunodeficiency virus (HIV) as dual infection with malaria may possibly facilitate geographical expansion of malaria especially in areas where HIV burden is high. Additionally, transient and repeated increases in HIV viral load arise as a result of repeated episodes of malaria in dual infections and may also be an important factor facilitating
the spread of HIV in sub-Saharan Africa [1, 2]. The exact nature of the relationship between HIV and malaria infection continues to be a subject of controversy. People living with HIV are at increased risk of clinical malaria which worsens over time as the immune system is suppressed, thus increasing the risk of malaria treatment failure [2]. Despite some reports that HIV does not have effect on malaria infection, malaria parasite density has been found to be significantly higher among HIV infected compared to HIV negative individuals [3]. The major challenges faced by people living with HIV are opportunistic infections like malaria and a range of other pathogenic infections, resulting in significant mortality [4]. In conformity with World Health Organization (WHO) recommendations on antiretroviral therapy (ART) program in developing countries, cotrimoxazole (CTX) prophylaxis is now an integral part of standard ART program [5]. This remains a major and important strategy for preventing most opportunistic infections among HIV infected individuals, including malaria infection [6]. In addition to CTX prophylaxis, some ART regimens [7] and insecticide-treated bed nets [2] have been reported to reduce the risk of malaria among HIV infected individuals. Unsurprisingly, discontinuation of CTX among HIV infected adults receiving ART has resulted in progressive increases in malaria burden and parasitemia [8]. Data evidence suggests that ART boosts immunity and reduces the incidence of malaria among HIV infected compared to HIV infected non-ART individuals; hence, it may possibly have indirect implication in malaria control [9]. Of particular importance among such ART regimens are protease inhibitors which have been reported to have antimalarial effects [10, 11] and have been shown to have potential ability to reduce malaria episode and prevalence [12].

HIV and malaria dual infections, particularly Plasmodium falciparum species, are both pathogens that induce significant perturbation and activation of the immune system. Such dual infections have been reported as the two most important health problems of developing countries, including Nigeria, accounting for more than 4 million annual deaths globally [13].

Studies have also provided evidence that anemia is the most commonly encountered hematological abnormality in HIV and malaria dual infected individuals [14–18]. However, other authors have reported different findings [19, 20]. Some studies have reported on the association between malaria and its effect on very limited hematological parameters among HIV and malaria dual infected patients without information on malaria density count [21–24]. In most sub-Saharan African countries, where the burden of HIV and malaria dual infections is incidentally high, comprehensive evaluation of hematological parameters should be considered. Thus far, only one study in Jos, Nigeria, has evaluated the effect of malaria parasite density on hemoglobin level only among HIV-infected population [25]. The major objective of this study was to determine the predictive association of malaria parasite density with hematological parameter changes among HIV infected adults attending two antiretroviral treatment clinics in Kano, Nigeria.

2. Methodology

2.1. Settings. This study was conducted between June 2015 and May 2016 in two public secondary health facilities, namely, Infectious Diseases Hospital (IDH) Kano and Murtala Muhammad Specialist Hospital (MMSH) Kano in Northwest Nigeria. The two facilities were purposefully selected because, first, IDH was the first public secondary health facility to commence ART services in Kano state followed by MMSH. Second, both facilities have high patient volume and presumed availability of previous patients’ information and data in both electronic management system and individual patient folders. Third, necessary ART laboratory equipment to support monitoring of patients was available.

2.1.1. Infectious Disease Hospital Kano. IDH Kano is located at France road, Sabon Gari, Fagge local government area of Kano state (Latitude 12.0113828′N and longitude 8.530433′E) within the savanna. The facility was established in the early 1960s as an isolation unit for smallpox patients. Subsequently, the facility was expanded into a fully fledged secondary level state-owned public hospital which now caters for all epidemic diseases prevalent in the state. The hospital provides services to a catchment area around Kano and neighboring states as well as to patients from the Republic of Niger. Presently, the hospital has a capacity of about 250 beds and a new multidrug resistant (MDR) tuberculosis clinic with three additional wards. With funds from the President’s Emergency Plan for Aids Relief (PEPFAR) through the United States Agency for International Development (USAID), Family Health International (FHI-360) in collaboration with Kano state government has been providing comprehensive ART program support to the facility since February 2005 till date. The ART laboratory provides HIV serological screening and ART monitoring testing as well as other tests such as pregnancy tests, hepatitis B and C, syphilis, and microscopy for malaria and tuberculosis diagnosis. Since inception, a total of about 7,000 HIV-positive patients are currently receiving ART as of July 2019.

2.1.2. Murtala Muhammad Specialist Hospital Kano. MMSH Kano is located at old Kano city metropolis (latitude 11.998190′N and longitude 8.522948′E) in Northwest Nigeria within the savanna. MMSH started service in 1926, and presently, the hospital has over 500 beds with an average of about 6000 outpatient encounters daily based on records. Through similar funding mechanism to that of IDH, comprehensive ART program support was started since August 2006. The ART laboratory provides similar services to those of IDH Kano. Since inception, a total of about 5,000 HIV positive patients are receiving ART as of July 2019.

2.2. Ethical Approval and Consent to Participate. The research protocol was reviewed and approved by Kano State Hospitals Management Board Ethical Committee (REF:
HMB/GEN/488/1 of 17th April 2015). All respondents voluntarily participated in the study, and signed individual consent forms before enrollment into the study.

2.3. Study Design, Eligibility, and Sample Size Determination. This was a cross-sectional study involving (randomly selected) consenting HIV-infected adults of both sexes aged 18 years and more and attending HIV treatment and care clinics of IDH Kano and MMSH Kano. We estimated the sample size with STATA software using formula for hypothesis testing of two-mean comparison. The estimates were based on assumptions of similar studies data in Nigeria [20, 26] and considered outcomes variables for our calculation (hemoglobin concentration, red blood cells, and platelets count). To determine and obtain an effect size of $1.5 \times 10^{12}/l$ for the red blood cells, a total of 200 participants per group was required to provide an 80% power in detecting this difference, assuming a two-tailed test and significance level of 5%. Details of sample size analysis were reported previously [27]. Of all outcomes, RBC yielded the largest sample size and hence was adopted for this study. Further adjustment of 5% nonresponse was made, and we eventually enrolled 761 participants from IDH and 786 participants from MMSH. A total of 26 participants with incomplete details were excluded giving a total of 1521 participants for the study.

2.4. Inclusion and Exclusion Criteria. Participants that visit Infection Disease Hospital Kano and Murtala Muhammad Specialist Hospital Kano to access antiretroviral services were approached and recruited into the study, having satisfied the following inclusion criteria:

(i) Adults aged 18 years and above
(ii) Confirmed HIV infection
(iii) Duly registered into the antiretroviral treatment (ART) program at both hospitals

2.5. Exclusion Criteria. Exclusion criteria include the following:

(i) Pregnant women
(ii) Any HIV-infected participant who has been on antimalarial drugs in the past two weeks
(iii) All those who did not consent to participate

2.6. Malaria Diagnosis, Parasite Density Determination, and Hematological Parameter Estimation. In brief, malaria parasites were screened, using malaria rapid diagnostic test (RDT) kits as described by the manufacturers (Standard Diagnostics Bioline, 2013). Regardless of RDT results, the blood smear microscopy method was used for confirmation. Blood sample collection, malaria diagnosis, and hematological parameters determination procedures had been previously described [27]. Malaria parasite density was determined more accurately using the actual white blood cells count per microliter, unlike the assumed white blood cells count of 8000 WBC/μl estimation recommended by the WHO [28]:

\[
\text{malaria parasite density estimation} = \frac{(\text{number of parasite count} \times \text{patient actual white blood cell count})}{\text{number of white blood cell count 200 or 500}}.
\]

Hematological parameters and platelets were estimated using an automated Sysmex XP-300 analyzer. To produce quality results with precision and accuracy, daily analysis of EIGHTCHECK control stabilized blood consisting of low, medium, and high levels of controls was done according to manufacturer instruction [29].

2.7. Data Collection and Statistical Analysis. All data collected were entered into Microsoft Excel files and reviewed for correctness, completeness, and consistency. Data confidentiality was ensured through delinking participant names from serial and enrollment number and restricting data access to only authorized research team members.

Cleaned data were imported into Statistical Package for Social Sciences (SPSS) software version 23.0 for analysis. Univariate analysis which includes descriptive statistics like frequencies, percentages, and exploration of the distribution of all variables of interest was performed. Association between categorical variables was tested using the chi-square test, i.e., association between HIV and malaria dual infected status in relation to age and gender. The mean values of hematological parameters by HIV/malaria dual infected status were generated and compared using the independent sample t-test. The association of MPDC with hematological parameters that showed statistically significant difference in the initial analysis was further tested using simple linear regression analysis. All tests were two-tailed with a significance set at 5% (0.05).

3. Results

3.1. Basic Characteristics and Clinical Information of Studied Participants. A total of 1521 HIV-positive individuals consisting of 1074 (70.6%) females and 447 (29.4%) males with a mean and standard deviation of 37.20 ± 10.41 and age range of 18–78 years were evaluated. Majority (79.8%) were of Hausa/Fulani ethnicity with 85% residing in urban settings. Greater proportion (71.3%) of the studied population had completed some level of education from primary to
tertiary levels (Table 1). A major proportion (45.9%) of the studied participants were self-employed while about 12% were civil servants and about 19% were unemployed at the time of this study. More than half (57.1%) of the study population were married, followed by approximately 23% who had lost their spouses. Over three quarters (79.2%) of the participants did not complain about their health at the time of visit during this study. Among those who had health complaints, about 38% complained of fever/headache/others combined, while about 32% complained of body pain/body weakness/others (Table 1). About 74% of participants reported using insecticide treated mosquito bed nets. Of those who used the treated bed nets, majority (80.3%) used them consistently for seven days per week (Table 1). Table 2 shows clinical information such as ART status, WHO staging, and CTX daily use.

3.2. Prevalence of HIV and Malaria Coinfection in Association with Sociodemographic Characteristics (Age and Gender).

In this study, the percentage of HIV and malaria dual infection was 25.4% based on the gold standard method (blood smear microscopy). Almost all (99.2%) of the HIV and malaria dual infections were due to *Plasmodium falciparum* species. Dual infections of *Plasmodium falciparum* and *Plasmodium vivax* species was observed in only 3 participants (0.8%). Analysis based on age group revealed that a majority (35.7%) of HIV and malaria dual infected individuals were in the 60-year and above age groups. Prevalence of HIV and malaria dual infection was similar in both genders. Overall, age group and gender did not show a statistically significant difference in prevalence of HIV and malaria dual infection (Table 3).

3.3. Pattern of Hematological Parameters and Its Association with Malaria Parasite Density Count among HIV and Malaria Dual Infected Participants.

A total of 16 hematological parameters were evaluated and compared among participants who were HIV and malaria dual infected and those who were HIV infected only. These 11 parameters showed a statistically significant mean difference between HIV infection only and HIV and malaria dual infection. The parameters were (1) packed cell volume, (2) hemoglobin concentration, (3) red blood cell, (4) mean cell volume, (5) mean cell hemoglobin concentration, (6) mean cell hemoglobin, (7) absolute lymphocyte count, (8) neutrophil differential count, (9) lymphocyte differential count, (10) mixed differential count, and (11) red cell distribution width. Eight hematological parameters (1) packed cell volume, (2) hemoglobin concentration, (3) red blood cell, (4) mean cell hemoglobin, (5) mean cell hemoglobin concentration, (6) mean cell volume, (7) absolute lymphocyte count, and (8) red cell distribution width) showed significantly higher mean among HIV infected individuals without malaria (Table 3).

Furthermore, we estimated malaria parasite density count (MPDC) and its association with hematological parameters among the HIV and malaria dual infected participants. Mean MPDC was 265 ± 31.8 (SD) cells/μl with a range of 20 to 2500 cells/μl (Table 3). Subsequent analysis of

| Variable                          | Number (%) |
|-----------------------------------|------------|
| Gender                            |            |
| Male                              | 447 (29.4) |
| Female                            | 1074 (70.6)|
| Age group (years)                 |            |
| Less than 30                      | 331 (21.8) |
| 30–39                             | 596 (39.2) |
| 40–49                             | 377 (24.8) |
| 50–59                             | 161 (10.6) |
| 60 and above                      | 56 (3.7)   |
| Place of residence                |            |
| Rural                             | 227 (14.9) |
| Urban                             | 1294 (85.1)|
| Marital status                    |            |
| Married                           | 868 (57.1) |
| Single                            | 194 (12.8) |
| Divorced                          | 112 (7.4)  |
| Widow/widower                     | 347 (22.8) |
| Educational status                |            |
| No formal education               | 451 (29.7) |
| Some primary education            | 80 (5.3)   |
| Completed primary                 | 295 (19.4) |
| Completed secondary               | 518 (34.1) |
| Completed tertiary                | 177 (11.6) |
| Ethnicity                         |            |
| Hausa/Fulani                      | 1214 (79.8)|
| Yoruba                            | 31 (2.0)   |
| Igbo                              | 52 (3.4)   |
| Others                            | 224 (14.7) |
| Complaints reported               |            |
| No                                | 1204 (79.2)|
| Yes                               | 317 (20.8) |
| Type of complaints                |            |
| Fever/headache/others             | 120 (37.9) |
| Body pain/weakness/others         | 100 (31.6) |
| Stomach upset/others              | 50 (15.8)  |
| Body rashes/chest pain/stooling   | 25 (7.9)   |
| Vomiting/others                   | 22 (6.9)   |
| Treated bed nets usage            |            |
| No                                | 399 (26.2) |
| Yes                               | 1122 (73.8)|
| Frequency of net usage/week       |            |
| 1-2 days/week                     | 24 (2.1)   |
| 3-4 days/week                     | 129 (11.5) |
| 5-6 days/week                     | 67 (6.0)   |
| 7 days/week                       | 902 (80.3) |
| Occupation                        |            |
| Civil servant                     | 186 (12.2) |
| Farmer                            | 35 (2.3)   |
| Business                          | 515 (33.9) |
| Artisan                           | 24 (1.6)   |
| Student                           | 56 (3.7)   |
| Housewife                         | 320 (21.0) |
| Unemployed                        | 285 (18.7) |
| Others                            | 100 (6.6)  |

11 blood count parameters showed significant difference among the HIV and malaria dual infected participants, revealing that MPDC was associated with changes in seven
Table 2: Clinical information of HIV-infected participants attending two selected ART clinics in Kano from June 2015 to May 2016 (n = 1521).

| Variables                  | Number (%) |
|----------------------------|------------|
| ART status                 |            |
| ART                        | 1288 (84.7)|
| Non-ART                    | 233 (15.3)|
| ART start year             |            |
| 2005                       | 54 (3.6)   |
| 2006                       | 34 (2.2)   |
| 2007                       | 130 (8.5)  |
| 2008                       | 156 (10.3) |
| 2009                       | 155 (10.2) |
| 2010                       | 112 (7.4)  |
| 2011                       | 82 (5.4)   |
| 2012                       | 106 (7.0)  |
| 2013                       | 165 (10.8) |
| 2014                       | 178 (11.7) |
| 2015                       | 349 (23.0) |
| ART regimen (n = 1288)     |            |
| TDF/3TC/EFV                | 529 (41.1) |
| AZT/3TC/NVP                | 746 (57.9)|
| Others                     | 13 (1.0)   |
| Current WHO stage          |            |
| Stage I                    | 348 (22.9) |
| Stage II                   | 680 (44.7) |
| Stage II                   | 313 (20.6) |
| Stage IV                   | 180 (11.8) |
| Daily dose of cotrimoxazole|            |
| No                         | 749 (49.2) |
| Yes                        | 772 (50.8) |

ART: antiretroviral therapy; AZT: zidovudine; EFV: efavirenz; NVP: nevirapine; 3TC: lamivudine; WHO: World Health Organization.

out of the 11 parameters, and the association was statistically significant. For every unit increase in MPDC, Hb decreased significantly by 0.98 g/dl, RBC by 0.252 × 10^12/L, MCHC by 1.76 g/dl, lymphocytes by 5.68%, and absolute lymphocyte count by 0.083 × 10^9/L (Table 5). Conversely, neutrophils and RWD increased by 6.96% and 0.021, respectively, for every unit increase in MPDC. These relationships were all statistically significant (p < 0.05) (Table 5).

4. Discussion

4.1. Summary of Main Findings. We observed a 25% prevalence of HIV and malaria dual infections in two ART clinics across two local government areas of Kano state of Nigeria. *Plasmodium falciparum* species accounted for 99% of malaria infection, and the rest were mixed infections of *Plasmodium falciparum* and *Plasmodium vivax*. In addition, mean MPDC among HIV and malaria coinfected individuals was 265 ± (SD) 31.8 cell/μL and ranged between 20 and 2,500 parasite/μL.

The means of 11 hematological parameters were significantly different between HIV monoinfected and HIV and malaria dual infected participants. Among dual infected participants, MPDC was observed to be a significant predictor of changes in seven out of eleven hematological parameters evaluated.

4.2. Comparison with Existing Literature

4.2.1. Prevalence of HIV and Malaria Dual Infection. The dual infections burden of 25% in this study was similar to that in other previous studies in Nigeria in Benue [9], Jos [30], and Kano [27] states, where the prevalence of dual infections was reported as 20.5%, 24%, and 27%, respectively. The current findings of dual infections of HIV and malaria were however lower compared to some other previous studies that reported 32.2% in Kano [31], 33.5% in Ondo [32], 47.7% in Lagos [18], 74.3% in Benin City [24], and 93.3% in Port Harcourt [26] all in Nigeria. Conversely, observed dual infections prevalence in this study was higher than reports of 2.9% in Lagos [18], 7.2% in Kogi [33], and 18.9% in southeast Nigeria [34]. As of the time of this study, none of our participants were on antimalaria drugs. Notably, those on antimalaria therapy in the past two weeks were under one of the study exclusion criteria.

Compared to other African countries, we observed a higher dual infection prevalence than 15.5% and 11.7% reported in two studies in Ghana [17, 35], 10% in South Africa [36], 17.1% in Ethiopia [37], and 19.9% pooled prevalence from meta-analysis of 23 studies across Africa [14]. Elsewhere, higher dual infections prevalence of 61.7% and 33% was reported in two separate studies in Mozambique [15, 38]. Recent comprehensive and more convincing data from a systematic review reported a 0.7%–47.5% prevalence of HIV and malaria dual infections among nonpregnant and adult population across sub-Saharan Africa [39]. Arguably, we believe that wide range and variation in prevalence of HIV and malaria dual infections may be multifactorial in nature. Factors such as number of participants examined, immunity and viral load of participants, frequency of malaria exposure, study design, period of study (raining or dry season), and ratio of non-ART and ART naïve participants may influence results among different populations.

4.2.2. Association of HIV and Malaria Dual Infection with Age and Gender. Prevalence of HIV and malaria dual infected burden analysis in association with gender revealed similar pattern in both sexes with no statistically significant difference. This was consistent with gender distribution data in studies conducted in Myanmar [40] and Mozambique [38] and other previous studies conducted across different states in Nigeria [9, 16, 24, 27]. However, the above observations varied with findings of Akinbo et al. who reported a statistically significant higher dual infection prevalence among male participants compared to their female counterparts in Kogi state, Nigeria [33].

HIV and malaria dual infections prevalence showed similar pattern among most age groups except those aged 60 years and more that revealed higher dual infections. Irrespective of this observation, overall, there was no statistically significant difference in dual infections prevalence observed across various age groups as previously reported in IDH Kano [27]. In contrast, significantly higher dual infections among age group of 19–24 years were observed in Kogi state,
TABLE 3: Prevalence of malaria parasite among HIV infected participants in relation to sociodemographic characteristics (age and gender) and density count among study participants attending two selected public ART clinics in Kano, Nigeria (n = 1521).

| Variables | Malaria positive n (%) | Malaria negative n (%) | Chi-square test statistic | p value |
|-----------|------------------------|------------------------|--------------------------|---------|
| RTD MP parasite species *Pf* and *Pv* | 250 (16.4) | 1271 (83.7) | — | — |
| Prevalence of malaria and HIV | 386 (25.4) | 1135 (74.6) | — | — |
| BSM MP parasite species *Pf* | 383 (25.2) | — | — | — |
| BSM MP parasite species *Pf* and *Pv* | 3 (0.2) | — | — | — |
| Overall *Pf* specie prevalence | 383 (99.2) | — | — | — |
| Mixed infection prevalence | 3 (0.8) | — | — | — |

Age group (years)

| Less than 30 (n = 331) | 92 (27.8) | 239 (72.2) | 6.499 | 0.165 |
| 30–39 (n = 596) | 141 (23.7) | 455 (76.3) | — | — |
| 40–49 (n = 377) | 88 (23.3) | 289 (76.7) | — | — |
| 50–59 (n = 161) | 45 (28.0) | 116 (72.0) | — | — |
| 60 and above (n = 56) | 20 (35.7) | 36 (64.3) | — | — |

Gender

| Male (n = 447) | 114 (25.5) | 333 (74.5) | 0.005 | 0.942 |
| Female (n = 1074) | 272 (25.3) | 802 (74.7) | — | — |

Malaria density count

| Malaria density count mean ± SD cells/μl | 265 ± 31.8 | — | — | — |
| Malaria density range cells/μl | 20–2500 | — | — | — |

BSM: blood smear microscopy; MP: malaria parasites; NS: no significant difference; n: number examined; Pf: *Plasmodium falciparum*; Pv: *Plasmodium vivax*; RTD: rapid diagnosis test; SD: standard deviation. *Significant at p < 0.05.

Table 4: Comparison of hematological parameters of HIV only and HIV and malaria dual infected participants attending two selected public ART clinics in Kano, Nigeria (n = 1521).

| Variable | HIV+ & malaria+ (n = 386) | HIV+ only (n = 1135) | t-test | p value |
|----------|---------------------------|---------------------|-------|---------|
| Hb (g/dl) | 10.95 ± 2.26 | 11.64 ± 1.85 | 5.42 | 0.001* |
| PCV (%) | 33.00 ± 6.21 | 35.42 ± 5.00 | 6.93 | 0.001* |
| WBC (×10^9/L) | 6.13 ± 2.87 | 5.95 ± 2.22 | -0.737 | 0.461 |
| Platelet (×10^12/L) | 263 ± 18.8 | 261 ± 18.2 | 0.022 | 0.983 |
| RBC (×10^12/L) | 3.79 ± 0.73 | 3.95 ± 0.70 | 3.77 | 0.001* |
| MCV (fl) | 87.78 ± 11.17 | 91.13 ± 10.99 | 5.16 | 0.001* |
| MCHC (g/dl) | 33.12 ± 2.57 | 32.81 ± 2.46 | -2.10 | 0.036* |
| MCH (pg) | 29.19 ± 4.71 | 30.02 ± 4.58 | 3.05 | 0.002* |
| Neutrophil (%) | 50.56 ± 13.69 | 48.73 ± 12.78 | -2.37 | 0.017* |
| Lymphocyte (%) | 39.00 ± 12.77 | 42.11 ± 11.10 | -3.53 | 0.001* |
| Mixed (%) | 9.93 ± 6.02 | 9.14 ± 5.85 | -2.27 | 0.024* |
| Abs neut (×10^9/L) | 4.42 ± 0.23 | 4.20 ± 0.21 | -1.69 | 0.910 |
| Abs lymph (×10^9/L) | 2.29 ± 1.02 | 3.50 ± 0.18 | 3.04 | 0.002* |
| Abs mixed (×10^9/L) | 1.91 ± 0.12 | 1.80 ± 0.11 | -1.86 | 0.630 |
| RDW-SD (%) | 48.83 ± 6.29 | 49.79 ± 6.83 | -2.40 | 0.016* |
| PDW | 10.80 ± 0.08 | 10.70 ± 0.08 | -1.34 | 0.180 |

Abs neut: absolute neutrophil; abs lymph: absolute lymphocyte count; Hb: hemoglobin; MCV: mean cell volume; MCHC: mean cell hemoglobin concentration; PCV: packed cell volume; PDW: platelet distribution width; SD: standard deviation; WBC: white blood cell; RBC: red blood cell; RDW: red cell distribution width. *Significant at p < 0.05.

Nigeria [33]. Another study in Mozambique reported that younger age group (40 years and below) could be a significant predictor of malaria among HIV dual infected individuals [38]. Evidence from recent systematic review has provided more insight; that is, malaria and HIV dual infections is associated with an increased occurrence of clinical parasitemia, severe malaria, high parasite density, and viral load, which in turn negatively impact immunity among various groups of patients [39].

4.2.3. Differences in Mean Hematological Parameters between Participants with HIV and Malaria Dual Infection and Those with HIV Monoinfection. Out of the 16 hematological parameters evaluated, 11 showed statistically significant mean difference between HIV and malaria dual infected and HIV monoinfected participants. Of those 11 hematological parameters, higher mean values were observed in seven parameters among HIV mono-infected compared to dual infected participants (Table 3). Results of the current study varied from findings by Erhabor and colleagues [26] who observed significantly higher pancytopenia among parasitized participants compared to nonparasitized control group due to the effects of dual infections. However, our findings were similar to an Ethiopia observation that revealed higher prevalence of anemia and thrombocytopenia among dual infected individuals compared to HIV negative individuals with malaria parasitemia and those without malaria...
parasitemia [16]. Furthermore, a study conducted in Myanmar observed that HIV and malaria coinfections significantly lower hemoglobin concentration, suggesting the possibility that coinfections may increase malaria density, further worsening malaria disease severity [40].

### 4.2.4. Association between Malaria Parasite Density Count and Hematological Parameters among Participants with HIV and Malaria Dual Infection

With simple linear regression analysis, we demonstrated that MPDC was a significant predictor of changes in seven (Table 5) out of the 11 (Table 4) hematological parameters that were shown in our preliminary analyses to be significantly different between HIV monoinfected and HIV and malaria coinfected patients. Aside from well reported side effects of granulocytopenia and anemia associated with ZDV-containing ART regimen, anemia among HIV infected individuals has been shown to be more broadly multifactorial in origin, and three basic pathophysiologic mechanisms of anemia in HIV infection have been postulated [41]: decreased RBC production, increased RBC destruction, and ineffective RBC production. To this extent, attribution of cause and effect association of anemia in HIV infection to specific ART regimen alone may not be plausible; therefore continuous evaluation to ascertain specific cause of anemia among HIV infected individuals is critical while also ensuring that adequate monitoring and interventions are put in place [42]. Besides hematological parameters, we had provided evidence that there exists statistically significant ($p < 0.05$) variation in MPDC in relation to ART regimen, cotrimoxazole prophylaxis status, fever status, and CD+4 count [43]. The overall mean white blood cells count of $5.99 \pm 2.40 \text{cells} \times 10^{9/L}$ observed in this study was similar to $5.5 \text{cells} \times 10^{9/L}$ reported among general population in Brazil—a malaria-endemic country [44]. Unexpectedly, the reference interval value for WBC count among Nigerians was lower (male $4.40 \pm 0.86$, female $4.61 \pm 1.05 \times 10^{9/L}$) [45] compared to HIV monoinfected participants in our study. In addition, low WBC count among the general population has been observed in two malaria-endemic zones [44, 45]. The risk of overestimating MPDC may arise from the use of the assumed mean WBC count of $8.0 \times 10^{9/L}$ recommended by the WHO [28]. Such claims should trigger the need for further studies across Nigeria and elsewhere to ascertain facts. Regional and demographic variables may have contributed to such variation between assumed WHO mean WBC count and the actual individual values.

### 4.3. Strengths and Limitations of the Study

The strengths of this study include the large sample size across two local government areas, which gave the study enough statistical power and potential for generalization of the study findings among HIV positive participants this setting. In addition, the actual mean white blood cell count for each individual was determined and used for MPDC estimation instead of the assumed WHO value [28]. Thus, MPDC estimation in this study can be considered relatively reliable.

Notably, the hematology analyzer Sysmex XP-300 available at the two laboratories for routine hematology work was limited because it is a three-part differential count autoanalyzer (neutrophils, lymphocytes, and mixed population) unlike a five-part differential count autoanalyzer. Therefore, mixed white blood cell types consisting of monocyte, basophils, and eosinophils cells were reported as mixed white blood cell population. A total of 51 data items were excluded in the final analysis because of incomplete information both in the clinical and the laboratory area.

We recommend further studies such as prospective cohort design with focus on HIV and malaria dual infection interaction, as well as impact of viral load, hematological parameters, and MPDC to provide more information on effect of HIV and malaria dual infection in endemic areas. Based on the distribution of WBC count among HIV participants, MPDC should be estimated and considered as an integral component of ART programs in malaria-endemic settings.

### 5. Conclusion

Dual infection of HIV and malaria burden was 25% among studied participants with no significant difference by age group and gender. Eleven blood cell count parameters were significantly different between HIV and malaria dual infected individuals and HIV monoinfected individuals.
MPDC was a significant predictor of changes in seven blood cell count parameters. Diagnosing malaria, especially in advanced HIV infection including MPDC determination to monitor possible changes in hematological parameters, should be considered as an integral part of ART program in endemic settings.

Data Availability

Data associated with this study are available in this paper in the form of tables, and any other data needed are available on reasonable request through the corresponding author.

Ethical Approval

The research protocol was reviewed by Kano State Hospital Management Board Ethical Committee with a written approval (REF: HMB/GEN/488/1 of 17th April 2015).

Consent

All respondents voluntarily participated in the study and signed individual consent forms before they were enrolled in the study.

Disclosure

The views expressed in this article were those of the authors and do not in any way reflect those of Family Health International (FHI-360) or the other institutions of the authors.

Conflicts of Interest

The authors declared that they have no conflicts of interest.

Authors’ Contributions

FEJ, TIO, and HAM contributed to study conceptualization and design. FEJ, TIO, HAM, and SAA were responsible for methods and materials. FEJ and TIO carried out laboratory investigation. SAA, FEJ, HAM, and TIO performed formal analysis and interpretation of data. TIO and HAM supervised the study. FEJ and SAA drafted the first manuscript. All authors provided resources, contributed to the review and editing processes of the manuscript, and approved the final copy of the submitted manuscript.

Acknowledgments

The authors would like to appreciate both facilities healthcare workers, especially the laboratory staff of both hospitals who provided support and conducive atmosphere that enabled the authors to successfully conduct this study.

References

[1] L. J. Abu-Raddad, P. Patnaik, and J. G. Kublin, “Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa,” Science, vol. 314, no. 5805, pp. 1603–1606, 2006.

[2] L. Slutsker and B. J. Marston, “HIV and malaria: interactions and implications,” Current Opinion in Infectious Diseases, vol. 20, no. 1, pp. 3–10, 2007.

[3] E. K. Rutto, J. Nyagol, J. Oyugi et al., “Effects of HIV-1 infection on malaria parasitemia in milo sub-location, western Kenya,” BMC Research Notes, vol. 8, no. 1, p. 303, 2015.

[4] C. C. Chang, M. Crane, J. Zhou et al., “HIV and co-infections,” Immunological Reviews, vol. 254, no. 1, pp. 114–142, 2013.

[5] World Health Organisation (WHO), Guidelines the Use of Antiretroviral Drugs for Treating and Consolidated Guidelines, World Health Organisation, Geneva, Switzerland, 2013.

[6] C. Manyando, E. M. Njunju, U. D’Alessandro, and J. P. V. Geertruyden, “Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review,” PLoS One, vol. 8, no. 2, Article ID e56916, 2013.

[7] R. Kasirye, B. Baisley, P. Munderi, and H. Grosskurth, “Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa,” Tropical Medicine and International Health, vol. 20, no. 5, pp. 569–580, 2015.

[8] R. K. Ottichilo, C. S. Polvak, B. Guyah et al., “Malaria parasitemia and parasite density in antiretroviral-treated HIV-infected adults following discontinuation of cotrimoxazole prophylaxis,” Journal of Infectious Diseases, vol. 215, no. 1, pp. 88–94, 2017.

[9] E. U. Amuta, R. S. Houmosou, and A. W. Diya, “Malarial infection among HIV patients on antiretroviral therapy (ART) and not on ART: a case study of federal medical centre Makurdi, Benue State, Nigeria,” Asian Pacific Journal of Tropical Diseases, vol. 2, pp. S378–S381, 2012.

[10] C. Nsanzabana and P. J. Rosenthal, “In vitro activity of antiretroviral drugs against Plasmodium falciparum, Anti-microbial Agents and Chemotherapy, vol. 55, no. 11, pp. 5073–5077, 2011.

[11] R. P. Kasirye, H. Grosskurth, P. Munderi et al., “Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults,” AIDS, vol. 31, no. 4, pp. 577–582, 2017.

[12] S. Greenhalgh, M. Ndeffo, A. P. Galvani, and S. Parikh, “The epidemiological impact of HIV antiretroviral therapy on malaria in children,” AIDS, vol. 29, no. 4, pp. 473–482, 2015.

[13] A. Alemu, Y. Shiferaw, Z. Addis, B. Mathewos, and W. Birhan, “Effect of malaria on HIV/AIDS transmission and progression,” Parasites & Vectors, vol. 6, no. 1, p. 18, 2013.

[14] C. Naing, N. K. Sandhu, and V. N. Wai, “The effect of malaria and HIV co-infection on anemia,” Medicine, vol. 95, no. 14, Article ID e3205, 2016.

[15] A. Saracino, E. A. Nacarapa, É. A. d. C. Massinga et al., “Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique,” Malaria Journal, vol. 11, no. 1, p. 241, 2012.

[16] O. Ojurongbe, O. A. Oyeniran, O. A. T. Ali et al., “Prevalence of Plasmodium falciparum parasitaemia and its correlation with haematological parameters among HIV-positive individuals in Nigeria,” Journal of Tropical Medicine, vol. 2014, Article ID 161284, 6 pages, 2014.

[17] S. Tay, K. Badu, A. A. Mensah, and S. Y. Gbedema, “The prevalence of malaria among HIV seropositive individuals and the impact of the co-infection on their hemoglobin levels,” Annals of Clinical Microbiology and Antimicrobials, vol. 14, no. 1, p. 10, 2015.

[18] A. O. Sanyaolu, A. F. Fagbenro-Beyioku, W. A. Oyibo, O. S. Badaru, O. S. Onyeabor, and C. I. Nnaemeka, “Malaria...
and HIV co-infection and their effect on haemoglobin levels from three healthcare institutions in Lagos, Southwest Nigeria,” *African Health Sciences*, vol. 13, no. 2, pp. 295–300, 2013.

[19] G. G. Tchinda, J. Atashili, E. A. Achidi, H. L. Kanga, A. L. Njunda, and P. M. Ndume, “Impact of malaria on hematological parameters in people living with HIV/AIDS attending the laquituninie hospital in douala, Cameroon,” *PLoS One*, vol. 7, no. 7, Article ID e40553, 2012.

[20] P. E. Etusim, C. A. Ihemanma, F. O. Nduka, P. E. Melariri, and O. Ukpia, “Comparative study on the haematological characteristics of malaria infected and malaria non-infected persons referred to art/HIV laboratory, Abia State University Teaching Hospital, Aba, Abia State,” *International Journal of Scientific Research in Multidisciplinary Studies*, vol. 5, pp. 100–112, 2013.

[21] K. S. Subramaniam, J. Skinner, E. Ivan et al., “HIV malaria co-infection is associated with atypical memory B cell expansion and a reduced antibody response to a broad array of *Plasmodium falciparum* antigens in Rwandan adults,” *PLoS One*, vol. 10, no. 4, Article ID e0124412, 2015.

[22] C. C. Onyenekwe, N. Ukibe, S. C. Meludu et al., “Possible biochemical impact of malaria infection in subjects with HIV co-infection in Anambra State, Nigeria,” *Journal of Vector Borne Diseases*, vol. 45, no. 4, pp. 151–156, 2008.

[23] C. J. Uneke, O. Ogbu, P. U. Inyama, and G. I. Anyanwu, “Malaria infection in HIV-seropositive and HIV-seronegative individuals in Jos-Nigeria,” *Journal of Vector Borne Diseases*, vol. 42, no. 4, pp. 151–154, 2005.

[24] C. E. Omoti, C. K. Ojide, P. V. Lofor, E. Eze, and J. C. Eze, “Prevalence of parasitemia and associated immunodeficiency among HIV-malaria co-infected adult patients with highly active antiretroviral therapy,” *Asian Pacific Journal of Tropical Medicine*, vol. 6, no. 2, pp. 126–130, 2013.

[25] O. N. Goselle, C. O. E. Onwuliri, and V. A. Onwuliri, “Malaria infection in HIV/AIDS patients and its correlation with packed cell volume (PCV),” *Journal of Vector Borne Diseases*, vol. 46, no. 3, pp. 205–211, 2009.

[26] O. Erhabor, S. Babatunde, and K. E. Uko, “Some haematological parameters in Plasmodial parasitized HIV-infected Nigerians,” *Nigerian Journal of Medicine*, vol. 15, no. 1, pp. 55–55, 2006.

[27] F. E. Jegede, T. I. Oyeyi, S. A. Abdulrahman et al., “Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria,” *PLoS One*, vol. 12, no. 3, Article ID e0174233, 2017.

[28] WHO, *Methods Manual for Malaria Microscopy, Method Identification and Qualification of Malaria in Thick and Thin Blood Film*, WHO, Geneva, Switzerland, 2015.

[29] Analyzer AH, *Instructions for Use*, Sysmex Stand Oper Proc Lab Users, 2012.

[30] M. O. Iroezindu, E. I. Agaba, E. N. Okeke et al., “Prevalence of malaria parasitaemia in adult HIV-infected patients in Jos, North-central Nigeria,” *Nigerian Medical Journal*, vol. 21, no. 2, pp. 209–213, 2012.

[31] Z. Iliyasu, M. Babashani, I. S. Abubakar, A. A. Salahudeen, and M. H. Aliyu, “Clinical burden and correlates of HIV and malaria co-infection, in northwest Nigeria,” *Acta Tropica*, vol. 128, no. 3, pp. 630–635, 2013.

[32] A. K. Onifade, E. O. Akanni, and O. O. Mewoye, “Incidence of malaria infection among human immunodeficiency virus patients in Ondo state, Nigeria,” *Middle-East Journal of Scientific Research*, vol. 2, no. 2, pp. 48–53, 2007.

[33] F. O. Akinbo, P. J. Anate, D. B. Akinbo et al., “Prevalence of malaria among HIV patients on highly active antiretroviral therapy in Kogi state, North Central Nigeria,” *Annals of Nigerian Medicine*, vol. 10, no. 1, pp. 11–15, 2016.

[34] C. C. Onyenekwe, N. Ukibe, S. C. Meludu et al., “Prevalence of malaria as co-infection in HIV-infected individuals in a malaria endemic area of southeastern Nigeria,” *Journal of Vector Borne Diseases*, vol. 44, no. 4, pp. 250–254, 2007.

[35] D. N. A. Tagoe and J. Boachie, “Assessment of the impact of malaria on CD4+ T cells and haemoglobin levels of HIV-malaria co-infected patients,” *The Journal of Infection in Developing Countries*, vol. 6, no. 9, pp. 660–663, 2012.

[36] C. Cohen, A. Karstaedt, J. Frean et al., “Increased prevalence of severe malaria in HIV-infected adults in South Africa,” *Clinical Infectious Diseases*, vol. 41, no. 11, pp. 1631–1637, 2005.

[37] H. B. Beyene, M. Tadesse, H. Disassa, and M. B. Beyene, “Concurrent *Plasmodium* infection, anemia and their correlates among newly diagnosed people living with HIV/AIDS in Northern Ethiopia,” *Acta Tropica*, vol. 169, pp. 8–13, 2017.

[38] F. D. Gennaro, C. Marotta, D. Pizzol et al., “Prevalence and predictors of malaria in human immunodeficiency virus infected patients in Beira, Mozambique,” *International Journal of Environment Research and Public Health*, vol. 15, no. 9, pp. 2032 pages, 2018.

[39] T. E. Kwenji, “Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies,” *Research and Reports in Tropical Medicine*, vol. 9, pp. 123–136, 2018.

[40] S. Rattanapunya, J. Kuesap, W. Chajaroenkul, R. Rueangweerayut, and K. Na-Bangchang, “Prevalence of malaria and HIV coinfection and influence of HIV infection on malaria disease severity in population residing in malaria endemic area along the Thai-Myanmar border,” *Acta Tropica*, vol. 145, pp. 55–60, 2015.

[41] P. A. Volberding, A. M. Levine, D. Dieterich et al., “Anemia in HIV infection: clinical impact and evidence-based management strategies,” *Clinical Infectious Diseases*, vol. 38, no. 10, pp. 1454–1463, 2004.

[42] T. C. Adias, E. Uko, and O. Erhabor, “Anaemia in human immunodeficiency virus infection: a review,” *Nigerian Journal of Medicine*, vol. 15, no. 3, 2007.

[43] H. A. Mbah, F. E. Jegede, S. A. Abdulrahman, and T. I. Oyeyi, “Evaluation of standard diagnostic rapid test kits for malaria diagnosis among HIV patients in Kano, Nigeria,” *African Journal of Laboratory Medicine*, vol. 7, no. 1, pp. 1–8, 2018.

[44] E. R. Alves-Junior, L. T. Gomes, D. Ribatski-Silva et al., “Assumed white blood cell count of 8,000 cells/µl overestimates malaria parasite density in the Brazilian amazon,” *PLoS One*, vol. 9, no. 4, Article ID e94193, 2014.

[45] T. M. Mork fich, T. M. Mork fich et al., “Comprehensive reference ranges for hematology and clinical chemistry laboratory parameters derived from normal nigerian adults,” *PLoS One*, vol. 9, no. 5, Article ID e93919, 2014.